Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

780.67
+1.390.18%
Post-market: 780.00-0.6700-0.09%16:58 EDT
Volume:1.45M
Turnover:1.13B
Market Cap:739.87B
PE:66.67
High:783.55
Open:780.46
Low:773.00
Close:779.28
Loading ...

Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?

Motley Fool
·
15 Jun

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial

Reuters
·
14 Jun

Down 12%, Should You Buy the Dip on Eli Lilly?

Motley Fool
·
13 Jun

UBS Reiterates Buy Rating on Eli Lilly Stock (LLY) and Lauds Pricing Strategy

TIPRANKS
·
13 Jun

UBS Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
13 Jun

US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads

MT Newswires Live
·
13 Jun

Trump Wants Cheaper Drugs Like Europe Has. How It Works. -- Barrons.com

Dow Jones
·
12 Jun

Eli Lilly (LLY) Developing New Muscle-Boosting Drug

TIPRANKS
·
12 Jun

Should You Buy Eli Lilly Stock Before June 22?

Motley Fool
·
11 Jun

BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says

Reuters
·
11 Jun

Eli Lilly & Co. Stock Rises 4.3%, Outperforms Competitors

Dow Jones
·
11 Jun

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live
·
11 Jun

Lilly taking ‘aggressive stance’ with virtual health partners, says Citi

TIPRANKS
·
11 Jun

Health Rounds: Patients drop fewer pounds with weight-loss drugs in real world than in trials

Reuters
·
11 Jun

Drug pricing reform talks with US government lack clarity, industry executives say

Reuters
·
11 Jun

Market Chatter: Lilly to Only Work With Telehealth Companies That Don't Sell Copycat Zepbound

MT Newswires Live
·
11 Jun

Lilly to Only Work With Telehealth Companies That Don't Sell Copycat Zepbound, Bloomberg Reports

MT Newswires Live
·
11 Jun

BUZZ-Novo shares rise after report on Parvus building stake

Reuters
·
10 Jun

Eli Lilly Strikes $870 Million Deal to Develop Long-Acting Obesity Treatments

TIPRANKS
·
10 Jun

UBS Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
10 Jun